Trial Profile

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dutasteride (Primary) ; Bicalutamide; Goserelin; Hydrocortisone; Ketoconazole
Indications Prostate cancer
Focus Pharmacodynamics
Acronyms TAPS
Sponsors GlaxoSmithKline

Most Recent Events

13 Feb 2021 Results of pooled analysis of post-RP outcomes from four clinical trials (NCT00298155; NCT00924469; NCT01547299; NCT02268175) presented at the 2021 Genitourinary Cancers Symposium
26 Mar 2017 Status changed from active, no longer recruiting to completed.
09 Dec 2013 Results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com